0
August 1996, Vol 114, No. 8 >
ARTICLE | August 1996

Will Latanoprost Be the 'Wonder' Drug of the '90s for the Treatment of Glaucoma? FREE

Eve J. Higginbotham, MD
Arch Ophthalmol. 1996;114(8):998-999. doi:10.1001/archopht.1996.01100140206015
Text Size: A A A
Published online
Article
References
Comments

One OF the challenges we have as clinicians who treat patients with glaucoma is to encourage the use of antiglaucoma medications on a long-term basis. It is difficult enough to remember to take medications daily. Noncompliance among our patients remains an ongoing issue. The adverse effects that are associated with many of these antiglaucoma medications can be intolerable for a large segment of the affected population and do not endear our patients to continue their therapy. Ocular burning, irritation, headaches, blurred vision, and wheezing are a few of the symptoms that may be noted on periodic visits. Consider also the changes that can occur in pulse rate and the level of high-density lipoprotein cholesterol and the interaction with systemic medications that the patient may already be using on a daily basis.

It is no wonder that the Moorfield1 study found that in patients with glaucoma, surgery was more effective

REFERENCES

1 +
Migdel C, Gregory W, Hitchings R.  Long-term functional outcome after early surgery compared with laser and medicine in open-angle glaucoma . Ophthalmology . 1994;;101:1651-1657.
2 +
Lichter PR.  Collaborative Initial Glaucoma Treatment Study (CIGTS) . In: Clinical Trials Supported by the National Eye Institute . Bethesda, Md: National Institutes of Health; 1993;:77-79. NIH publication 93-2910.
3 +
Bito LZ, Draga A, Bianco J, Camras CB.  Long-term maintenance of reduced intraocular pressure by daily or twice daily topical application of prostaglandins to cat and rhesus monkey eyes . Invest Ophthalmol Vis Sci . 1983;;24:312-319.
4 +
Alm A, Villumsen J.  Effects of topically applied PGF2α and its isopropylester on normal and glaucomatous human eyes . Prog Clin Biol Res . 1989;;312:447-458.
5 +
Stjernschantz J, Resul B.  Phenyl-substituted prostaglandin analogs for glaucoma treatment . Drugs Future . 1992;;17:691-701.
6 +
Camras CB, Schumer RA, Marsk A, et al.  Intraocular pressure reduction with PhXA34, a new prostaglandin analogue, in patients with ocular hypertension . Arch Ophthalmol . 1992;;110:1733-1738.
7 +
Alm A, Villumsen J, Tornquist P, et al.  Intraocular pressure reducing effect of PhXA41 in ocular hypertensive patients: a placebo controlled double masked dose finding study . Invest Ophthalmol Vis Sci . 1992;;33( (suppl) ):1247.
8 +
Mishima HK, Masuda K, Kitazawa Y, Azuma I, Araie M.  A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension: a 12-week study . Arch Ophthalmol . 1996;;114:929-932.
9 +
Camras CB, for the United States Latanoprost Study Group.  Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month, masked multicenter trial in the United States . Ophthalmology . 1996;;103:138-147.
10 +
Camras CB, Zhan G-L, Wang Y-L, Tons CB, Bito LZ.  Effect of sympathectomy and prostaglandin (Pg) analogue (latanoprost) treatment on iris color in pigmented rabbits . Invest Ophthalmol Vis Sci . 1995;;36( (suppl) ):S720.
11 +
Ziai N, Dolan JW, Kacere RD, Brubaker RF.  The effects on aqueous dynamics of PhXA41, a new prostaglandin F2α analogue, after topical application in normal and ocular hypertensive human eyes . Arch Ophthalmol . 1993;;111:1351-1358.
12 +
Crawford K, Kaufman PL.  Pilocarpine antagonizes prostaglandin F2α-induced ocular hypotension in monkeys: evidence for enhancement of uveoscleral out-flow by prostaglandin F2α . Arch Ophthalmol . 1987;;105:1112-1116.
13 +
Kashiwagi K, Lindsey JD, Kashiwagi F, Weinreb RN.  Extracellular matrix changes induced by prostaglandins in cultured human ciliary muscle cells . Invest Ophthalmol Vis Sci . 1995;;36( (suppl) ):S729.
14 +
Camras CB, Friedman AH, Rodrigues MM, Tripathi BJ, Tripathi RC, Podos SM.  Multiple dosing of prostaglandin F2α or epinephrine on cynomolgus monkey eyes . Invest Ophthalmol Vis Sci . 1988;;29:1428-1436.
15 +
Rulo AH, Greve EL, Hoyng PF.  Additive effect of latanoprost, a prostaglandin F2α analogue, and timolol in patients with elevated intraocular pressure . Br J Ophthalmol . 1994;;78:899-902.
16 +
Alm A, Widengard I, Kjellgren D, et al.  latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol . Br J Ophthalmol . 1995;;79:12-16.

First Page Preview

First page PDF preview

Figures

Tables

Interactive Graphics

Video

Country-Specific Mortality and Growth Failure in Infancy and Yound Children and Association With Material Stature

Use interactive graphics and maps to view and sort country-specific infant and early dhildhood mortality and growth failure data and their association with maternal

1 +
Migdel C, Gregory W, Hitchings R.  Long-term functional outcome after early surgery compared with laser and medicine in open-angle glaucoma . Ophthalmology . 1994;;101:1651-1657.
2 +
Lichter PR.  Collaborative Initial Glaucoma Treatment Study (CIGTS) . In: Clinical Trials Supported by the National Eye Institute . Bethesda, Md: National Institutes of Health; 1993;:77-79. NIH publication 93-2910.
3 +
Bito LZ, Draga A, Bianco J, Camras CB.  Long-term maintenance of reduced intraocular pressure by daily or twice daily topical application of prostaglandins to cat and rhesus monkey eyes . Invest Ophthalmol Vis Sci . 1983;;24:312-319.
4 +
Alm A, Villumsen J.  Effects of topically applied PGF2α and its isopropylester on normal and glaucomatous human eyes . Prog Clin Biol Res . 1989;;312:447-458.
5 +
Stjernschantz J, Resul B.  Phenyl-substituted prostaglandin analogs for glaucoma treatment . Drugs Future . 1992;;17:691-701.
6 +
Camras CB, Schumer RA, Marsk A, et al.  Intraocular pressure reduction with PhXA34, a new prostaglandin analogue, in patients with ocular hypertension . Arch Ophthalmol . 1992;;110:1733-1738.
7 +
Alm A, Villumsen J, Tornquist P, et al.  Intraocular pressure reducing effect of PhXA41 in ocular hypertensive patients: a placebo controlled double masked dose finding study . Invest Ophthalmol Vis Sci . 1992;;33( (suppl) ):1247.
8 +
Mishima HK, Masuda K, Kitazawa Y, Azuma I, Araie M.  A comparison of latanoprost and timolol in primary open-angle glaucoma and ocular hypertension: a 12-week study . Arch Ophthalmol . 1996;;114:929-932.
9 +
Camras CB, for the United States Latanoprost Study Group.  Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month, masked multicenter trial in the United States . Ophthalmology . 1996;;103:138-147.
10 +
Camras CB, Zhan G-L, Wang Y-L, Tons CB, Bito LZ.  Effect of sympathectomy and prostaglandin (Pg) analogue (latanoprost) treatment on iris color in pigmented rabbits . Invest Ophthalmol Vis Sci . 1995;;36( (suppl) ):S720.
11 +
Ziai N, Dolan JW, Kacere RD, Brubaker RF.  The effects on aqueous dynamics of PhXA41, a new prostaglandin F2α analogue, after topical application in normal and ocular hypertensive human eyes . Arch Ophthalmol . 1993;;111:1351-1358.
12 +
Crawford K, Kaufman PL.  Pilocarpine antagonizes prostaglandin F2α-induced ocular hypotension in monkeys: evidence for enhancement of uveoscleral out-flow by prostaglandin F2α . Arch Ophthalmol . 1987;;105:1112-1116.
13 +
Kashiwagi K, Lindsey JD, Kashiwagi F, Weinreb RN.  Extracellular matrix changes induced by prostaglandins in cultured human ciliary muscle cells . Invest Ophthalmol Vis Sci . 1995;;36( (suppl) ):S729.
14 +
Camras CB, Friedman AH, Rodrigues MM, Tripathi BJ, Tripathi RC, Podos SM.  Multiple dosing of prostaglandin F2α or epinephrine on cynomolgus monkey eyes . Invest Ophthalmol Vis Sci . 1988;;29:1428-1436.
15 +
Rulo AH, Greve EL, Hoyng PF.  Additive effect of latanoprost, a prostaglandin F2α analogue, and timolol in patients with elevated intraocular pressure . Br J Ophthalmol . 1994;;78:899-902.
16 +
Alm A, Widengard I, Kjellgren D, et al.  latanoprost administered once daily caused a maintained reduction of intraocular pressure in glaucoma patients treated concomitantly with timolol . Br J Ophthalmol . 1995;;79:12-16.

Correspondence

Submit a Letter
CME Course for:


You need to register in order to view this quiz.


To understand the clinical management of acute heart failure syndromes.
Accreditation Information The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
To view and print your certificate and access a summary of your CME courses go to My CME.
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s “Cited By” API will populate this tab (http://www.crossref.org/citedby.html).
Compression-Only CPR: Pushing the Science Forward
Cone
AAM 2010;304:1493-1495.
All you need to read in the other general journals
BMJ 2010;341:c5893-c1494.
Submit a Comment

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

© 2012 American Medical Association. All Rights Reserved.
Powered bySilverchair Information Systems